Korean Medication Algorithm Project for Bipolar Disorder 2018 (KMAP-BP 2018): Fourth Revision
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP) was first published in 2002 through an expert consensus of opinion, and updated in 2006, 2010, and 2014. This study constitutes the fourth revision of the KMAP-BP. METHODS: A 50-item questionnaire was used to obtain the consensus of experts regarding pharmacological treatment strategies for various phases of adult bipolar disorder and six items for pediatric bipolar disorder. The review committee included 84 Korean psychiatrists and 43 child and adolescent psychiatry experts. RESULTS: The preferred first-step strategies for acute mania were the combination of a mood stabilizer (MS) and an atypical antipsychotic (AAP), MS monotherapy, and AAP monotherapy. A combination of a MS and an AAP, and AAP monotherapy were preferred for psychotic mania. The first-step strategies for mild to moderate bipolar depression were monotherapy with MS, AAP, or lamotrigine (LMT), and the combination of a MS and an AAP or LMT, or a combination of an AAP and LMT. The combination of two among a MS, AAP, and LMT were preferred for non-psychotic severe depression. A combination of a MS and an AAP or the combination of an AAP with an antidepressant or LMT were the first-line options for psychotic severe depression. CONCLUSION: The recommendations of the KMAP-BP 2018 have changed from the previous version by reflecting recent developments in pharmacotherapy for bipolar disorder. KMAP-BP 2018 provides clinicians with a wealth of information regarding appropriate strategies for treating patients with bipolar disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A., & Keller, M. B. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.530 · Cited by 2,106
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Pacchiarotti, I., Bond, D. J., Baldessarini, R. J., Nolen, W. A., Grunze, H., Licht, R. W., Post, R. M., Berk, M., Goodwin, G. M., Sachs, G. S., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13020185 · Cited by 770
Determinants of adherence to treatment in bipolar disorder: A comprehensive review
Leclerc, E., Mansur, R. B., & Brietzke, E. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.01.036 · Cited by 171
An update of safety of clinically used atypical antipsychotics
Orsolini, L., Tomasetti, C., Valchera, A., Vecchiotti, R., Matarazzo, I., Vellante, F., Iasevoli, F., Buonaguro, E. F., Fornaro, M., Fiengo, A. L. C., et al. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1201475 · Cited by 135
Selle, V., Schalkwijk, S., Vázquez, G., & Baldessarini, R. (2014) · Pharmacopsychiatry · doi:10.1055/s-0033-1363258 · Cited by 128
Lindström, L., Lindström, E., Nilsson, M., & Höistad, M. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.02.012 · Cited by 122
Cruz, N., Sanchez-Moreno, J., Torres, F., Goikolea, J. M., Valentí, M., & Vieta, E. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990344 · Cited by 121
Polytherapy in Bipolar Disorder
Lin, D., Mok, H., & Yatham, L. N. (2006) · CNS Drugs · doi:10.2165/00023210-200620010-00003 · Cited by 91
Montejo, Á. L., Arango, C., Bernardo, M., Carrasco, J. L., Crespo-Facorro, B., Cruz, J. J., Del Pino-Montes, J., García-Escudero, M. A., García-Rizo, C., González-Pinto, A., et al. (2017) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2017.02.003 · Cited by 75
Cited by
Fountoulakis, K. N., Tohen, M., & Zarate, C. A. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.10.003 · Cited by 146
Development and implementation of guidelines for the management of depression: a systematic review
Lee, Y., Brietzke, E., Cao, B., Chen, Y., Linnaranta, O., Mansur, R. B., Cortes, P., Kösters, M., Majeed, A., Tamura, J. K., et al. (2020) · Bulletin of the World Health Organization · doi:10.2471/blt.20.251405 · Cited by 45
Self-citationCai, L., Chen, G., Yang, H., & Bai, Y. (2023) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000449 · Cited by 11
“One lurasidone study which enrolled patients from Asia and Europe showed greater efficacy in the 20–60 mg/ day group compared with the 80–120 mg/day group (Kato et al., 2020); however, similar efficacy was observed between the 20–60 mg/day group and the 80–120 mg/day group in a lurasidone study enrolling patients from…”
BackgroundInfluential
Metadata
- Authors
- Woo, Y. S., Bahk, W.-M., Lee, J. G., Jeong, J.-H., Kim, M.-D., Sohn, I., Shim, S.-H., Jon, D.-I., Seo, J. S., Min, K. J., Kim, W., Song, H.-R., & Yoon, B.-H.
- Venue
- Clinical Psychopharmacology and Neuroscience
- Published
- 2018-11-30
- Volume
- 16
- Issue
- 4
- Pages
- 434-448
- ISSN
- 1738-1088 (ISSN-L)
- 2093-4327
- OpenAlex
- W2898353727
- Cited by
- 35
- References
- 15
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.